AI Article Synopsis

  • The study found that clarithromycin (CAM) and azithromycin (AZM) have significantly higher concentrations in lung epithelial lining fluid (ELF) and alveolar macrophages (AMs) compared to plasma after oral administration in rats.
  • The area under the drug concentration-time curve (AUC) showed a notably higher ratio for CAM (12) versus plasma and even higher for AMs, indicating effective drug distribution and accumulation.
  • In vitro experiments revealed that the transport of CAM and AZM into AMs is enhanced by active transport mechanisms and can be inhibited by certain substances, indicating complex interactions in drug absorption and distribution in lung cells.

Article Abstract

The distribution characteristics of clarithromycin (CAM) and azithromycin (AZM), macrolide antimicrobial agents, in lung epithelial lining fluid (ELF) and alveolar macrophages (AMs) were evaluated. In the in vivo animal experiments, the time-courses of the concentrations of CAM and AZM in ELF and AMs following oral administration (50 mg/kg) to rats were markedly higher than those in plasma, and the area under the drug concentration-time curve (AUC) ratios of ELF/plasma of CAM and AZM were 12 and 2.2, and the AUC ratios of AMs/ELF were 37 and 291, respectively. In the in vitro transport experiments, the basolateral-to-apical transport of CAM and AZM through model lung epithelial cell (Calu-3) monolayers were greater than the apical-to-basolateral transport. MDR1 substrates reduced the basolateral-to-apical transport of CAM and AZM. In the in vitro uptake experiments, the intracellular concentrations of CAM and AZM in cultured AMs (NR8383) were greater than the extracellular concentrations. The uptake of CAM and AZM by NR8383 was inhibited by ATP depletors. These data suggest that the high distribution of CAM and AZM to AMs is due to the sustained distribution to ELF via MDR1 as well as the high uptake by the AMs themselves via active transport mechanisms.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bdd.767DOI Listing

Publication Analysis

Top Keywords

cam azm
28
lung epithelial
12
distribution characteristics
8
characteristics clarithromycin
8
macrolide antimicrobial
8
antimicrobial agents
8
epithelial lining
8
lining fluid
8
alveolar macrophages
8
cam
8

Similar Publications

Macrolide-resistant Mycoplasma pneumoniae (MRMP) infections have become increasingly prevalent, especially in East Asia. Whereas MRMP strains have point mutations that are implicated in conferring resistance, monitoring the antibiotic susceptibility of M. pneumoniae and identifying mutations in the resistant strains is crucial for effective disease management.

View Article and Find Full Text PDF

Signal of safety due to adverse drug reactions induced by tacrolimus with or without azithromycin.

Transpl Infect Dis

June 2022

Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Yokohama, Japan.

Article Synopsis
  • The study investigated the potential adverse interactions between azithromycin (AZM) and tacrolimus (TAC), particularly focusing on increased drug levels and acute kidney injury caused by their combination.
  • Data from the FDA's Adverse Event Reporting System was analyzed, revealing that while AZM combined with TAC may increase drug levels, it does not significantly raise the risk of acute kidney injury compared to TAC alone.
  • The findings suggest that while using AZM with TAC could lead to higher drug levels, the combination does not pose a significant risk for acute kidney injury, unlike other macrolide antibiotics such as clarithromycin (CAM) when used with TAC.
View Article and Find Full Text PDF

Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives.

Bioorg Med Chem Lett

July 2021

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Wenhua Road, Jinan 250012, China. Electronic address:

A novel series of 3-O-descladinosyl-3-keto-clarithromycin derivatives, including 11-O-carbamoyl-3-O-descladinosyl-3-keto-clarithromycin derivatives and 2',9(S)-diaryl-3-O-descladinosyl-3-keto-clarithromycin derivatives, were designed, synthesized and evaluated for their in vitro antibacterial activity. Among them, some derivatives were found to have activity against resistant bacteria strains. In particular, compound 9b showed not only the most significantly improved activity (16 µg/mL) against S.

View Article and Find Full Text PDF

complex (MABC) is an infectious agent associated with macrolide resistance and treatment failure. Despite drug-susceptibility testing for MABC isolates including clarithromycin (CAM), long-term treatment with azithromycin (AZM) for MABC disease is recommended. We compared phenotypic and genotypic resistance to AZM and CAM in clinical isolates and evaluated the accumulation of intrinsic macrolide resistance (AIM) and morphological changes by macrolides exposure.

View Article and Find Full Text PDF

The proton pump inhibitor lansoprazole (LPZ) inhibits the growth of several cancer cell lines, including A549 and CAL 27. We previously reported that macrolide antibiotics such as azithromycin (AZM) and clarithromycin (CAM) potently inhibit autophagic flux and that combining AZM or CAM with the epidermal growth factor receptor inhibitors enhanced their antitumor effect against various cancer cells. In the present study, we conducted the combination treatment with LPZ and macrolide antibiotics against A549 and CAL 27 cells and evaluated cytotoxicity and morphological changes using cell proliferation and viability assays, flow cytometric analysis, immunoblotting, and morphological assessment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!